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Malaria at Johannesburg Hospital
A retrospective study
K. T. JAIRAM, F. S. E. MONTEAGUDO, S. L. MOCH, I. HAVLlK
Summary
A total of 43 patients diagnosed as having malaria were
admitled to Johannesburg Hospital during 1988; 40 (94%)
were infected with Plasmodium falciparum. Only 26 patients
(60%) were recorded as having used prophylaxis of any kind;
chloroquine alone and in combination was used as prophy-
laxis by 17:. Patients were treated with quinine (alone or in
combination) in 67% of cases. In 42% of patients chloro-
quine-resistant malaria was considered a possibility.
S Air Med J 1990: 78: 467-469.
Patients and methods
Johannesburg Hospital has 833 beds at present and during
1988 there were approximately 32051 admissions. The hospital
serves as a tertiary referral centre and is a teaching hospital of
the University of the Witwatersrand. The records of the
Haematology Laboratory of the South African Institute for
Medical Research in Johannesburg, which serves the hospital,
were studied to identify all patients with positive malaria
smears admined during 1988. The medical records of these
patients were then obtained from the Medical Records Depart-
ment.
Results
TABLE I. INCIDENCE OF MALARIA IN DIFFERENT
AGE GROUPS
There were 43 positive blood smears from 32 male and 11
female patients (median age 30 years; range 3 - 66 years). The
incidence of malaria in the different age groups is shown in
Table I.
Over the last 10 - 15 years the deterioration in the incidence of
malaria in Mrica has been partly due to the increasing spread
of a Plasmodium falciparum population that is resistant to
chloroquine and other drugs. There have been reports of
cWoroquine-resistant P. falciparum malaria from regions such
as Ethiopia,! Kenya,2 East Mrica,3 northern Malawi4 and
Mozambique5 and cWoroquine resistance has also been con-
firmed in vicro in southern Mrica.6,7
The difficulty of malaria control in cWoroquine-resistant
parasites is further compounded by the toxicity of alternative
drugs that make it difficult to propose effective and safe
medication for chemoprophylaxis and therapy.
A selected group of malaria patients and the drugs used in
their therapy is reviewed. It is important to note that Johan-
nesburg Hospital is a tertiary referral centre and the patients
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Types of malaria
Infection with P. falciparum was the most common type of
malaria seen and occurred in 40 patients (94%). Two patients
were infected with P. vivax and P. ovale, respectively, and in 1
patient the type of malaria was not identified.
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TABLE IV. CLINICAL FEATURES ON ADMISSION













More than one sign was present in some patients.
TABLE V. LABORATORY ABNORMALITIES AND CLINICAL
COMPLICATIONS
TABLE VI. DRUGS USED FOR THERAPY
Drugs No. of patients %
Quinine combined with
tetracycline 23 53
Quinine alone 4 9
Chloroquine 4 9
Quinine combined with other
drugs 2 5
Details of therapy not available 10 24
Drugs used in therapy
In 42% of patients the possibility of chloroquine-resistant
malaria was considered. This assessment was reached because
the patient had become infected despite using adequate chloro-
quine prophylaxis, or because the patient did not respond to
initial therapy using chloroquine and was then treated with
another drug. Quinine combined with tetracycline was most































TABLE Ill. DRUGS USED AS PROPHYLAXIS






















Chloroquine + pyrimethamine +
proguanil
Pyrimethamine + sulphadoxine




Most patients presented with a 'flu-like illness - fever,
headache and splenomegaly being the major presenting signs
(Table IV). The median period. of duration of symptoms
before diagnosis was confIrmed was 4 days (range 1 - 30 days).
The regions where the patients were thought to have con-
tracted malaria are listed in Table II. Six patients travelled
through many malaria-endemic countries in Mrica and so a
definite area where they were infected could not be determined.
The three regions where patients most often contracted malaria
were Botswana, Malawi and Zimbabwe. None of the patients
in this smdy were thought to have contracted the disease in
South Mrica.
Prophylaxis
Twenty-six patients (60%) had taken prophylaxis of some
kind, while 10 patients had used no prophylactic agents (Table
Ill). Data from 7 patients were not available. Only 13 of the
26 patients who had taken prophylactic measures had used the
right dosage and, of these, only 11 continued taking medication
after returning from an endemic malaria area. Chloroquine
alone and in combination was used by 17 patients.
Laboratory abnormalities and clinical
complications
Laboratory abnormalities included thrombocytopenia,
anaemia, bilirubinaemia and leucopenia (Table V). Clinical
complications included cerebral malaria, acute renal failure
and adult respiratory distress syndrome (ARDS) (Table V).
Twenty-nine patients (67%) were treated with quinine (alone
or in combination) and side-effeets occurred in 12 (41%)
(nausea in 5 (17%), cinchonism in 4 (14%), hypoglycaemia in 1
(3%), and cinchonism together with hypoglycaemia in 2 (7%)).
While the data for the clinical course of 11 patients (26%)
remain unknown, 31 patients (72%) recovered, with the median
time spent in hospital being 7 days (range 2 - 17 days). One
death was recorded in a woman diagnosed as having cerebral
malaria, who presented late. She was in renal failure and coma
on admission and subsequently died, despite vigorous therapy.
Discussion
Three problem areas became apparent when reviewing the
data: (I) timeous diagnosis and correct management of malaria;
(il) effective and safe prophylaxis; and (iii) degree of chloro-
quine resistance.
Major shoncomings in the management of malaria are a
delay in diagnosis and inappropriate treatment.S Rapid diagnosis
can be made using thick and thin blood smears, but the
clinical features with which the patient presents and, in parti-
cular, a history of travel in an endemic area are also imponant
clues.
Morbidity due to malaria is serious, particularly if diagnosis
is delayed. The median duration of symptoms before diagnosis
was 4 days, with a range of 1 - 30 days in our study. Available
statistics suggest that many deaths in shon-stay travellers due
to malaria occur after rerum to their country of origin and lack
of prompt and adequate medical care are often responsible.9
In this study, 29 patients, including 4 with cerebral malaria,
were treated with quinine alone or in combination. In 11 of
these patients chloroquine therapy was starred but, because of
a lack of response, quinine was subsequently administered. In
8 patients quinine therapy was instituted immediately, possibly
because the patients had contracted malaria despite apparently
using adequate chloroquine prophylaxis. There appeared to be
no additional reason why quinine was administered immediately
to the remaining 10 members of this group.
In 42% of patients chloroquine-resistant malaria was con-
sidered possible. Although this was not proven, the assessment
is in keeping with current opinion about the frequency of
chloroquine resistance. The implications regarding prophylaxis
and therapy of malaria are significant.
The incidence of side-effects due to quinine was low and
those reponed resolved with dose reduction.
Our data indicate that only 26% of patients used adequate
prophylaxis. Adequate prophylaxis is imponant, since surveys
have indicated that patients with non-fatal infections have a
much higher rate of use of chemoprophylaxis than those who
die. 9 Details of recommended prophylaxis, although conten-
tious, are available. 1D-16
A common laboratory finding was thrombocytopenia, which
was shon-lived and was not associated with any bleeding
disorder. Cerebral malaria was seen in 4 patients. This diagnosis
was based on the clinical features with which the patients
presented, such as impairment of consciousness, acute convul-
sions, focal cerebral signs, coma and positive malaria smears. 17•18
ARDS was observed in 1 patient, who needed to be ventilated
and was treated in the respiratory intensive care unit. There
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was 1 death in a woman diagnosed as having cerebral malaria,
who presented late.
Future research in the field of malaria could include a study
of the characteristics of parasitised and non-parasitised red
blood cells. This may assist in understanding the mechanisms
~f resistance to drugs. The above observations suggest that the
risk of contracting malaria may be tninitnised by programmes
directed at encouraging the use of correct chemoprophylaxis
by travellers. Travellers should also be educated about the risk
of fatal malaria, and knowledge of diagnosis and treatment of
malaria by health care practitioners could be improved to
bener achieve this objective.
We would like to acknowledge the suppon of the Wellcome
Malaria Research Programme, Department of Experimental and
Oinical Pharmacology, University of the Witwa~ersrand.
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